2. Economic studies: excluded.
| Study ID | Status | Reasons for exclusion | Study type |
| Davies 2007 | Excluded | Allocation: randomised. Particiapants: schizophrenia. Interventions: first vs second generation antipsychotics. Outcomes: no specific outcome measures for trifluoperazine. |
Type A |
| Filippelli 2005 | Excluded | Allocation: randomised. Particiapants: schizophrenia. Interventions: atypical vs typical antipsychotics. Outcomes: no specific outcome measures for trifluoperazine. |
Type A |
| Galvin 1999 | Excluded | Allocation: not randomised. | N/A |
| Ghaemi 2001 | Excluded | Allocation: not randomised. | N/A |
| Hanrahan 2006 | Excluded | Allocation: randomised. Particiapants: schizophrenia. Interventions: atypical vs conventional antipsychotics. Outcomes: no specific outcome measures for trifluoperazine. |
Type A |
| Knapp 2008 | Excluded | Allocation: randomised. Particiapants: schizophrenia. Interventions: olanzapine vs other antipsychotics. Outcomes: no specific outcome measures for trifluoperazine. |
Type A |
| Lewis 1998 | Excluded | Allocation: randomised (systematic review). | N/A |
| Lewis 2006 | Excluded | Allocation: randomised (systematic review). | N/A |
| Martin 2006 | Excluded | Allocation: randomised (systematic review). | N/A |
| Mould 2009 | Excluded | Allocation: randomised. Particiapants: schizophrenia. Interventions: cost and effectiveness of ziprasidone, olanzapine, risperidone, haloperidol and clozapine (not trifluoperazine). |
Type A |
| Stargardt 2008 | Excluded | Allocation: not randomised. | N/A |
| Suttajit 2009 | Excluded | Allocation: randomised (systematic review). | N/A |